When Will the Ozempic Lawsuit Be Settled?

If you’re wondering when will the Ozempic lawsuit be settled, the timeline is still uncertain. Factors like the number of cases, legal procedures, and specific case details affect how long it may take. Ozempic settlements may take months or even years, depending on the complexity of your case.

If you or a loved one suffered injuries or side effects of weight loss or diabetes drugs like Wegovy, Olympic, Mounjaro, or Rybelsus, you have the right to hold the manufacturer accountable.

Contact Uptown Injury Law Ozempic lawyers at 917-540-8728 to get a free case review. Our team will determine how much compensation you’re owed and how to proceed with the legal action.

How Long Will the Ozempic Lawsuits Take to Settle?

The timeline for settling an Ozempic lawsuit can vary widely depending on the specifics of each case. While some cases may settle quickly, others could take months or even years to resolve. Factors like case complexity, available evidence, and ongoing litigation developments can all impact the duration.

As of August 2024, the number of lawsuits related to Ozempic and other GLP-1 receptor agonists has significantly increased. In just one month, the number of active cases in the ongoing class action lawsuit rose from 111 in July to 346 by August. This surge highlights the growing attention these cases are receiving, but it also means that the legal process may take longer as courts manage the increasing volume of claims.

On August 8, 2024, a status conference addressed key issues, including the progress of electronic Plaintiff Fact Sheets (e-PFS), ongoing developments in the discovery phase, and updates on temporarily stayed cases. This conference is just one of many steps in the complex litigation process, highlighting that the case is still in its early stages.

Ozempic Lawsuit 2024 Update

The Ozempic lawsuits have seen significant developments throughout 2024. The increasing number of case filings and significant court hearings are continuously shaping the direction and progress of the litigation.

Below is the most recent news on the Ozempic lawsuits. Be sure to check back frequently, as our ozempic attorneys regularly update this section with the newest developments.

August 8, 2024 – Status Conference Scheduled

On August 8, 2024, a status conference addresses various crucial aspects of the case. The discussion focused on the progress of the electronic Plaintiff Fact Sheets (e-PFS), ongoing developments in the discovery process, updates on cases temporarily stayed, and the planning of the upcoming Science Day. This conference highlighted the steady advancement of the case, ensuring that all procedural details were moving forward effectively.

August 4, 2024 – Surge in Class Action Case Count

From July to August 2024, the number of active cases in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation has increased significantly. In July 2024, there were 111 active lawsuits in MDL-3094. By August, this number increased to 346, reflecting a dramatic rise of 235 cases in just one month.

August 1, 2024 – New Lawsuit Filed by Illinois Resident

An Illinois man has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging failure to warn about the risks associated with Ozempic and Mounjaro. After taking Ozempic for diabetes management from October 2022 to January 2023 and later switching to Mounjaro, the plaintiff was hospitalized in June 2023 with severe abdominal pain.

He underwent surgery for ischemic bowel resection. His lawsuit, now transferred to the MDL in Pennsylvania, seeks compensation for medical expenses, pain, and suffering.

July 9, 2024 – Direct Filing of GLP-1 Lawsuits

As of July 9, 2024, plaintiffs can directly file their Ozempic lawsuits into MDL No. 3094. This new order aims to streamline administrative processes and centralize pretrial proceedings in the United States District Court for the Eastern District of Pennsylvania. Direct filing enhances efficiency by eliminating the need for initial case transfers and streamlining case management.

The order also introduces a new service process, where Eli Lilly and Novo Nordisk agree to accept email service instead of formal service.

July 8, 2024 – Status Conference Highlights

During the status conference on July 10, 2024, participants discussed key issues, including cross-cutting motion briefs, disputed provisions in the ESI protocol, and the discovery process. Plaintiffs resisted defendants’ attempts to delay litigation by focusing on causation, as they are eager to prepare for trial.

July 3, 2024 – Study Links Ozempic to Vision Loss

A recent study has highlighted a significant association between semaglutide, a GLP-1 receptor agonist in Ozempic, and nonarteritic anterior ischemic optic neuropathy (NAION), a condition that causes sudden vision loss. The study, involving over 16,800 patients, found that those taking semaglutide had a higher incidence of NAION compared to those using other diabetic medications.

For type 2 diabetic patients, the incidence of NAION was 8.9% among semaglutide users versus 1.8% among those on other drugs. In overweight or obese patients, the incidence was 6.7% compared to 0.8% for other weight-loss drugs.

July 1, 2024 – New Lawsuits Filed

On July 1, 2024, a new ozempic lawsuit was filed. It involved an Indiana woman who developed severe constipation, rectal bleeding, and vomiting after using Ozempic. An ultrasound revealed a bowel obstruction, which required treatment. The plaintiff claims that Ozempic’s label failed to adequately warn about its risks, significantly impacting her life.

This new case adds to the growing number of lawsuits alleging that Ozempic’s labeling inadequately discloses the risks associated with its use. Additionally, the increasing number of claims emphasizes the need for thorough review and updates to drug warnings to ensure patients are fully informed about potential side effects.

June 23, 2024 – Kansas Resident Sues Over Gastroparesis

A Kansas resident has filed a lawsuit against the manufacturer of Ozempic, alleging that the medication led to the development of gastroparesis and other severe health complications. The plaintiff, who used Ozempic from November 2019 to October 2022, experienced persistent vomiting, diarrhea, and abdominal pain.

The lawsuit seeks compensation for the plaintiff’s suffering and medical expenses, emphasizing the ongoing concerns about Ozempic’s safety and the need for adequate warnings on the drug’s label.

June 13, 2024 – District Judge Holds Hearing With Ozempic Lawyers

On June 13, 2024, Judge Marston held a hearing with ozempic lawyers. While the hearing did not result in any major developments, it highlighted the importance of maintaining progress in the litigation. The judge emphasized the need for continued advancement in the case to ensure timely resolution.

The hearing focused on procedural aspects and the ongoing preparation of cases. It highlighted the need for both sides to stay engaged and collaborative in advancing the litigation process, ensuring that all relevant issues are addressed efficiently.

June 10, 2024 – New Judge Takes Over Ozempic Litigation

In June 2024, U.S. District Judge Karen Marston in Philadelphia has taken over the Ozempic litigation. The case, involving over 10,000 personal injury lawsuits, was previously managed by the late U.S. District Judge Gene E.K. Pratter, who passed away in May. Judge Marston’s appointment signaled a renewed effort to push the litigation forward, with a focus on developing Plaintiff Fact Sheets to streamline the discovery process.

June 3, 2024 – Increase in MDL Cases

In May 2024, an additional dozen cases were added to the Ozempic MDL, bringing the total to 101 pending cases. The increasing case volume indicates a rising awareness and concern among patients regarding the potential risks associated with these medications. Moreover, it also highlights the need for ongoing legal and regulatory scrutiny of Ozempic and similar drugs.

May 23, 2024 – MDL Judge Passes Away

The litigation was temporarily stalled due to the tragic death of MDL Judge Gene E.K. Pratter. The Judicial Panel on Multidistrict Litigation must now appoint a new judge to oversee the proceedings.

May 21, 2024 – Agreement on Plaintiff Fact Sheet

Both sides in the litigation have nearly reached an agreement on a 13-page Plaintiff Fact Sheet and authorization form required from all plaintiffs. Both sides agreed to use Rubris, a third-party vendor, to handle electronic submissions of the PFS.

This agreement takes a significant step in organizing and streamlining the litigation process, allowing the parties to efficiently gather and review all relevant data.

May 18, 2024 – MDL Judge Schedules Science Day

Case Management Order #5, issued on May 18, 2024, scheduled a “Science Day” for June 14, 2024. This non-adversarial event will provide an overview of the medical and scientific issues pertinent to the Ozempic litigation. During Science Day, both parties will present evidence related to the medical and scientific aspects of the case.

May 1, 2024 – New Cases Added to MDL

The Ozempic MDL saw a rise in cases from 55 in February to 74 by April 1, 2024. This increase reflects the growing number of plaintiffs coming forward with claims related to Ozempic and similar drugs.

The upward trend in case numbers highlights patients’ increasing concern regarding the potential side effects of these medications. 

April 16, 2024 – Plaintiff Attorneys Refute Defendants’ Claims

On April 16, 2024, the plaintiffs’ attorneys disputed the defendants’ claims that their treatment methods were new and that they had provided enough warnings about the risks. The plaintiffs argue that the warnings were insufficient and that the risks associated with Ozempic and other GLP-1 receptor agonists were not properly communicated.

This refutation is part of the ongoing effort to hold drug manufacturers accountable for failing to warn sufficiently about potential risks. The plaintiffs are working to ensure the litigation addresses these critical issues and seeks appropriate redress for affected individuals.

April 10, 2024 – Leadership Dispute Among Plaintiff Firms

A leadership dispute among plaintiff firms has arisen, with one firm criticizing the process for selecting the leadership team as unfair and non-transparent. Despite this internal conflict, the ozempic lawyers in leadership are expected to guide the litigation to a successful settlement.

April 5, 2024 – Main Injuries in Ozempic Litigation

The Ozempic litigation primarily focuses on three types of injuries related to the drug’s impact on the digestive system:

• Gastroparesis: A condition that restricts stomach motility, causing nausea, vomiting, and pain.
• Ileus: A temporary pause in bowel motility leading to bloating, nausea, and vomiting.
• Bowel Obstruction: A serious condition where the intestines become blocked, requiring immediate medical attention.

April 2, 2024 – Increase in MDL Cases

The number of pending cases in the Ozempic MDL increased from 55 in February to 74 by April 1, 2024. The litigation is expected to grow as more individuals come forward with claims.

March 18, 2024 – Novo Nordisk’s Marketing Expenses

Novo Nordisk spent $11 million in 2022 on marketing Ozempic and its diabetes medications, including funding meals and travel for nearly 12,000 doctors. Critics argue that investing these funds in researching the drug’s side effects and long-term efficacy would have been more beneficial.

March 15, 2024 – First Status Conference Held

The first status conference in the Ozempic class action lawsuit took place on March 14, 2024, in Pennsylvania federal court. During this conference, the parties discussed organizational and procedural aspects, including the appointment of a leadership team and the development of plaintiff fact sheets.

The focus was on streamlining the litigation process and addressing the allegations of inadequate warnings about the drug’s side effects, such as gastroparesis—a condition impacting stomach function. Eighteen lawsuits have already been consolidated in the U.S. District Court for the Eastern District of Pennsylvania, with more cases pending consolidation.

February 29, 2024 – First Status Conference

A status conference for the Ozempic MDL is scheduled for March 14, 2024. This will provide insight into how U.S. District Judge Gene E.K. Pratter will handle the litigation, potentially setting the stage for future proceedings.

February 20, 2024 – Study on Psychiatric Side Effects

A recent study has highlighted a significant association between Ozempic and other GLP-1 receptor agonists with psychiatric side effects. This adds another layer of complexity to the ongoing litigation, raising concerns about the comprehensive understanding of these drugs’ risks.

February 12, 2024 – New Lawsuit Filed in New Jersey

A new ozempic lawsuit gallbladder was filed in New Jersey, alleging that the use of Ozempic resulted in a gallbladder injury that required surgical removal. This case shows the broad spectrum of claims, including those related to gallbladder issues, which are central to the ozempic lawsuit.

February 8, 2024 – Research on Weight Loss and Gastrointestinal Issues

Recent research has found that while Ozempic and similar medications promote weight loss, they may also increase the chances of gastrointestinal issues such as nausea and vomiting, particularly at higher doses.

February 5, 2024 – MDL Panel Consolidates Cases

The MDL Panel has announced that federal lawsuits involving Ozempic and similar drugs be consolidated under a federal judge in Philadelphia. This decision aims to centralize the litigation process and manage the growing number of cases more efficiently.

January 27, 2024 – Jurisdiction Ruling in Louisiana

Federal Judge James D. Cain Jr. ruled that Novo Nordisk has sufficient ties to Louisiana for jurisdiction in an Ozempic lawsuit. This decision impacts where and how cases can be pursued.

January 12, 2024 – Denied Request to Modify Claim

A Louisiana federal judge denied a request to modify a breach of express warranty claim against Novo Nordisk. The plaintiff alleges developing gastroparesis after using Ozempic, but the modification request was ruled untimely.

January 8, 2024 – Study on Suicide Risk

A study published in Nature contradicted previous concerns about suicide risks associated with GLP-1 receptor agonists, suggesting that these drugs might not increase the risk of suicide as previously thought.

January 6, 2024 – Disagreements on Consolidation

Defendants disagreed on consolidating the Mounjaro and ozempic lawsuits, with Eli Lilly opposing including their products in the combined litigation. The dispute highlights ongoing challenges in managing these cases.

January 1, 2024 – New Lawsuit in Louisiana

A recent lawsuit filed in Louisiana claims that Ozempic and Mounjaro caused serious health issues, including intense vomiting and tooth loss. The defendants contest the jurisdiction and the specifics of the plaintiff’s claims.

Novo Nordisk’s Defense Against the Lawsuits

Novo Nordisk has stated that their drugs, including Ozempic, are safe. They admit that users might experience gastrointestinal side effects, such as nausea or stomach discomfort. However, the company describes these side effects as mild, moderate, and temporary.

Moreover, Novo Nordisk highlights that these side effects are listed on the drug’s warning label. They argue that this labeling gives users a clear warning about the potential risks before they start taking the medication.

Ozempic Side Effects and Health Risks

Ozempic, a medication primarily prescribed to manage type 2 diabetes, has been linked to several serious and potentially life-threatening side effects. Among the most alarming is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition that causes sudden and irreversible vision loss. NAION occurs due to reduced blood flow to the optic nerve, making it a rare but severe risk for Ozempic users.

Another major concern is severe gastrointestinal complications, particularly stomach paralysis, also known as gastroparesis. This condition disrupts the stomach’s ability to empty its contents properly, resulting in chronic nausea, vomiting, severe bloating, and malnutrition.

The central allegation in the lawsuits is that Novo Nordisk failed to warn about these serious risks adequately. Although not officially approved, Novo Nordisk invested $1 million in promoting Ozempic for off-label weight management in non-diabetic patients.

Which Organs Does the Ozempic Affect the Most?

Ozempic, a medication containing semaglutide, significantly impacts various organs, with the gastrointestinal system being the most affected. Clinical studies have shown that gastrointestinal side effects are prevalent among users. 

For instance, nausea is reported by approximately 20% of patients, while vomiting occurs in about 11.5% and diarrhea in 11.3%. These symptoms arise from the drug’s ability to slow gastric emptying, which aims to control blood sugar in patients with type 2 diabetes.

The thyroid gland is another organ at risk. The FDA has issued warnings about the possibility of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), linked to semaglutide use. Although direct evidence in humans is limited, animal studies have shown an increased risk of thyroid tumors, leading to a need for long-term monitoring in patients using Ozempic.

Ozempic also has a notable impact on the pancreas. While large-scale studies like the SUSTAIN trials reported acute pancreatitis in a small percentage of patients, concerns remain about the potential for more severe pancreatic conditions, such as pancreatic cancer. The risk is considered low, but ongoing evaluation is crucial due to the drug’s relatively recent introduction. This concern has prompted numerous Ozempic lawsuit pancreatitis claims, with plaintiffs arguing that they did not receive adequate warnings about these potential risks.

In addition to these effects, the drug Ozempic has been linked to kidney and gallbladder issues. Acute kidney injury was observed in a small percentage of patients during the SUSTAIN trials. Gallbladder-related issues, such as cholelithiasis, were reported in about 1.4% of patients. These researches highlight the need for vigilant monitoring, as the drug’s full impact on these organs is still being studied.

How Much Is Ozempic Lawsuit Worth?

Generally, Ozempic lawsuit settlement amounts can vary based on the severity of your injuries and the specifics of your case. For cases involving severe side effects such as stomach paralysis or gallbladder injuries, settlements can range from $400,000 to $700,000.

The actual value of your ozempic lawsuit depends on several factors, including the extent of your medical issues, any lost wages, and the impact on your quality of life. Legal experts will evaluate these factors to determine a fair settlement amount based on the evidence and damages suffered.

So, if you’re facing serious health complications after taking Ozempic, it’s important to consult with an experienced ozempic lawyer. At Uptown Injury Law, PLLC, we can help you understand the potential value of your claim and guide you through the legal process. Call us at 917-540-8728 to get a free case review.

Who Qualifies for an Ozempic Lawsuit?

If you’ve experienced severe side effects like stomach paralysis, thyroid cancer, pancreatitis, or significant gastrointestinal issues after using Ozempic for 30 days or more, you may qualify for a lawsuit. If a doctor prescribed the medication off-label for weight loss and you have detailed medical records to support your claim, you might also be eligible.

Consulting with a skilled ozempic lawsuit lawyer can help determine if your case meets the necessary criteria. Schedule your free consultation now to explore your legal options.

How to File a Lawsuit Against Ozempic?

The first step in filing an Ozempic lawsuit is to consult with an attorney who specializes in Ozempic or GLP-1 receptor agonist cases. Your attorney will assist you in gathering evidence, including medical records and documentation of how your injuries are linked to the medication.

Your ozempic attorney will then file a complaint in the appropriate court. Many ozempic cases are now part of Multidistrict Litigation (MDL), a process for handling large numbers of related cases more efficiently. If your case is part of MDL, it will be consolidated with other similar cases for pretrial proceedings.

How MDL and Class Actions Work for Ozempic Lawsuits?

MDL consolidates individual lawsuits into one federal court for pretrial management, streamlining processes such as evidence gathering and legal motions. For Ozempic, MDL No. 3094 has been established in the Eastern District of Pennsylvania. This MDL includes cases alleging severe side effects from Ozempic and other GLP-1 receptor agonists such as Wegovy, Rybelsus, Trulicity, and Mounjaro. Each case within the MDL remains independent and may return to its original court for trial if not settled.

In contrast, a class action involves a single lawsuit representing a group of plaintiffs with similar claims. Although MDL is being used for Ozempic cases, a class action has not been initiated. MDL 3094 helps manage the pretrial phase of these cases efficiently, addressing common issues while allowing for individual outcomes.

Which Type of Compensation Can Plaintiffs Expect in Ozempic Cases?

As a plaintiff in an Ozempic lawsuit, you may receive various types of compensation based on your injuries and losses. These include:

• Medical Costs
• Lost Wages and Reduced Earning Capacity
• Out-of-Pocket Expenses
• Pain and Suffering
• Loss of Enjoyment of Life
• Psychological Impacts

Other Diabetes or Weight Drugs You Can File a Lawsuit Against

If you’ve experienced adverse effects from diabetes or weight-loss medications, you might consider filing a lawsuit against other similar drugs. Many of these medications, including other GLP-1 receptor agonists and semaglutide-based drugs, can have severe side effects that could entitle you to compensation. 

Here are some of the drugs you might be able to file a lawsuit against:

• Wegovy (semaglutide)
• Rybelsus (semaglutide)
• Trulicity (dulaglutide)
• Mounjaro (tirzepatide)
• Saxenda (liraglutide)

Contact Uptown Injury Law, PLLC Ozempic Attorneys to Get a Free Case Review

If you’ve experienced severe side effects from Ozempic or other GLP-1 receptor agonists, our dedicated team at Uptown Injury Law, PLLC, is here to help. With over 15 years of experience and $100 million secured for our clients, we understand the complexities of mass tort and product liability cases and are here to fight for your rights.

Why Choose Us?

• Free Case Review: Reach out for a no-obligation consultation to evaluate your case.
• Contingency Fee Basis: You don’t pay unless we win your case.
• Expertise You Can Trust: Our experienced attorneys will guide you through every step of the process.

Call us now at 917-540-8728 or fill out our online form to schedule your free case review.

FAQs